Blue Zone Wealth Advisors LLC Has $4.97 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Blue Zone Wealth Advisors LLC increased its stock holdings in Thermo Fisher Scientific Inc. by 7.5%, amassing a total value of $4.97 million by the end of the recent quarter.
• Institutional investors own 89.23% of Thermo Fisher Scientific's shares, indicating significant institutional interest in the company.
• Thermo Fisher Scientific reported $5.36 earnings per share for the last quarter, surpassing analysts' estimates and showing a 2.9% year-over-year revenue increase.

Blue Zone Wealth Advisors LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,248 shares of the medical research company's stock after purchasing an additional 858 shares during the quarter. Blue Zone Wealth Advisors LLC's holdings in Thermo Fisher Scientific were worth $4,966,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in TMO. Nuveen LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth about $532,360,000. EdgePoint Investment Group Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth about $172,139,000. Cohen Investment Advisors LLC increased its position in Thermo Fisher Scientific by 6,655.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after acquiring an additional 331,180 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Thermo Fisher Scientific by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after acquiring an additional 329,974 shares during the last quarter. Finally, Auto Owners Insurance Co raised its stake in shares of Thermo Fisher Scientific by 6,773.5% in the first quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company's stock worth $143,309,000 after acquiring an additional 283,810 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 1.8%

Shares of Thermo Fisher Scientific stock opened at $524.95 on Friday. The company has a market capitalization of $198.23 billion, a price-to-earnings ratio of 30.36, a PEG ratio of 2.90 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The firm's 50-day moving average price is $488.68 and its two-hundred day moving average price is $448.39.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TMO shares. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an "outperform" rating in a research note on Tuesday. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, October 4th. HSBC restated a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, UBS Group upped their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus target price of $593.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.